US2003195235A1PendingUtilityA1
Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
Priority: Apr 4, 2001Filed: Feb 24, 2003Published: Oct 16, 2003
Est. expiryApr 4, 2021(expired)· nominal 20-yr term from priority
A61P 9/10A61P 3/10A61P 43/00A61P 9/00A61P 9/12A61P 29/00A61P 25/00A61P 27/12A61P 3/04A61P 27/02A61K 31/421A61K 31/4164A61K 31/425A61P 15/00A61K 31/203A61K 31/70A61K 31/42A61K 31/41A61P 1/00A61K 31/426A61K 31/4196A61P 13/12A61K 31/415
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, comprising
(a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to said subject a jointly effective amount of an RXR modulator, said co-administration being in any order and the combined jointly effective amounts providing the desired therapeutic effect.
2 . The method of claim 1 , wherein the RXR modulator is an RXR agonist.
3 . The method of claim 1 , wherein the RXR modulator is selected from
(a) bexarotene; (b) 9-cis-retinoic acid; (c) AGN-4326; (d) LGD 1324; (e) LG 100754; (f) LY-510929; (g) LGD 1268; and (h) LG 100264.
4 . The method of claim 1 , wherein the RXR modulator is a compound of Formula (VI),
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
n and m are independently 0 or 1;
R 1 and R 2 are 1) independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, hydroxyl, acyl, amino, mono-substituted amino, di-substituted amino, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide or haloalkoxy; or 2) R 1 and R 2 together with the aromatic ring bonded thereto form a cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
R 3 and R 4 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, heteroaryl, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
A is —CR 6 R 7 — wherein R 6 and R 7 are independently or together hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, haloalkoxy; or R 6 and R 7 together form a cycloalkyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
Ar is Formula VII, VIII, IX or X:
wherein R 8 , R 9 and R 10 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylamide, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
R 5 is hydrogen, halogen, hydroxy, alkyl or substituted alkyl;
represents a bond present or absent; and
W, X, Y and Z are independently or together —C(O)—, —C(S)—, —S—, —O—, or —NH— residues.
5 . The method of claim 4 , wherein n is 1, R 1 and R 2 together with the aromatic ring bonded thereto form a substituted cycloalkyl optionally comprising 1 or 2 heteroatoms selected from O, S, NH or N-alkyl, and R 3 is alkyl or substituted alkyl.
6 . The method of claim 4 , wherein n is 1, A is —CR 6 R 7 — wherein R 6 and R 7 are independently or together alkyl, or R 6 and R 7 together form a cycloalkyl comprising 1 or 2 oxygen atoms and more preferably a 1,3-dioxolane ring.
7 . The method of claim 4 , wherein n is 1, the group
is 2,4-thiazolidinedione, 2-thioxo-4-thiazolidinedione, isoxazolidinedione, 2,4-imidazolidinedione or 2,4-thioxo-4-imidazolidinedione.
8 . The method of claim 4 , wherein n is 1, and the compound of Formula VI is selected from
3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-trifluoromethoxybenzylidene-2,4-thiazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzylidene-2,4-thiazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzylidene-2,4-thiazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzylidene-2-thioxo-2,4-thiazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzylidene-2-thioxo-2,4-thiazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzylidene-2-thioxo-2,4-imidazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzylidene-2-thioxo-2,4-imidazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzylidene-2,4-imidazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzylidene-2,4-imidazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzyl-2,4-thiazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzyl-2,4-thiazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzyl-2-thioxo-2,4-thiazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzyl-2-thioxo-2,4-thiazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzyl-2-thioxo-2,4-imidazolidinedione; 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzyl-2-thioxo-2,4-imidazolidinedione; 4-[2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1,3-dioxolane]benzyl-2,4-imidazolidinedione; and 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-propyl]benzyl-2,4-imidazolidinedione.
9 . The method of claim 4 , wherein the RXR modulator is MX-6054.
10 . The method of claim 1 , wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
11 . The method of claims 1 , 2 , or 4 , wherein the diabetes or Syndrome X, or associated symptoms or complication thereof is IDDM.
12 . The method of claims 1 , 2 , or 4 , wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is NIDDM.
13 . The method of claims 1 , 2 , or 4 , wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is IGT or IFG.
14 . The method of claims 1 , 2 , or 4 , further comprising administering to said subject a jointly effective amount of a third antidiabetic agent.
15 . The method of claim 14 , wherein the third antidiabetic agent is selected from
(aa) insulins, (bb) insulin analogues; (cc) insulin secretion modulators, and (dd) insulin secretagogues.
16 . The method of claim 15 , wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is IDDM.
17 . The method of claims 1 , 2 , 4 , or 8 , wherein the glucose reabsorption inhibitor is an SGLT inhibitor.
18 . The method of claim 17 , wherein the glucose reabsorption inhibitor is an SGLT1 inhibitor.
19 . The method of claim 17 , wherein the glucose reabsorption inhibitor is an SGLT2 inhibitor.
20 . The method of claim 17 , wherein the glucose reabsorption inhibitor is selected from a dihydrochalcone, a propiophenone, and a derivative thereof.
21 . The method of claim 20 , wherein the glucose reabsorption inhibitor is a compound of Formula (V)
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
Ar is aryl or heteroaryl;
OX is an optionally protected hydroxy group;
Y is hydrogen or alkyl; and
Z is glucopyranosyl wherein one or more hydroxy groups thereof may optionally be substituted with one or more groups selected from α-D-glucopyranosyl, alkanoyl, alkoxycarbonyl, and substituted alkyl.
22 . The method of claim 21 , wherein the glucose reabsorption inhibitor is a compound of Formula (IV)
wherein Ar is an aryl group, R 1 is hydrogen atom or an acyl group, R 2 is hydrogen atom, an acyl group or α-D-glucopyranosyl group, or R 1 and R 2 may combine together to form a substituted methylene group, R 3 and R 4 are each hydrogen atom or an acyl group, and OR 5 is a protected or unprotected hydroxy group or a lower alkoxy group.
23 . The method of claim 21 , wherein the glucose reabsorption inhibitor is a compound of Formula (III)
wherein R′ is a lower alkanoyl group, and R″ is a hydrogen atom, or R′ is a hydrogen atom, and R″ is a lower alkoxycarbonyl group.
24 . The method of claim 21 , wherein the glucose reabsorption inhibitor is a compound of Formula (II)
wherein X is an oxygen atom, a sulfur atom or a methylene group, OY is a protected or unprotected hydroxy group, Z is a β-D-glucopyranosyl group or 4-O-(α-D-glucopyranosyl)-β-D-glucopyranosyl group wherein one or more hydroxy groups of these groups may optionally be acylated, and the dotted line means the presence or absence of a double bond.
25 . The method of claim 21 , wherein the glucose reabsorption inhibitor is a compound of Formula (I)
wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a β-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected.
26 . The method of claim 25 , wherein the glucose reabsorption inhibitor is T-1095 or T-1095A
with one or more hydroxyl or diol protecting groups, or a pharmaceutically acceptable salt thereof.
27 . The method of claim 25 , wherein the glucose reabsorption inhibitor is T-1095 or T-1095A,
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.
28 . The method of claim 25 wherein the glucose reabsorption inhibitor is T-1095 or T-1095A with one or more hydroxyl or diol protecting groups, or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.
29 . The method of claim 28 wherein the glucose reabsorption inhibitor is T-1095.
30 . The method of claim 28 wherein the glucose reabsorption inhibitor is T-1095A.
31 . The method of claimS 2 , 3 , 4 , 8 , or 9 , wherein the glucose reabsorption inhibitor is selected from the glucose reabsorption inhibitors described in claim 25 or 28 .
32 . The method of claim 28 , wherein the jointly effective amount of T-1095 or T-1095A is from about 10 to 1000 mg.
33 . The method of claim 28 , wherein the jointly effective amount of T-1095 or T-1095A is an amount sufficient to reduce the plasma glucose excursion following a meal.
34 . A method for inhibiting the onset of diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising
(a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to said subject a jointly effective amount of an RXR modulator, said co-administration being in any order and the combined jointly effective amounts providing the desired prophylactic effect.
35 . The method of claim 34 , wherein said onset is from pre-diabetic state to NIDDM.
36 . A pharmaceutical composition comprising a glucose reabsorption inhibitor, a RXR modulator, and a pharmaceutically acceptable carrier.
37 . The pharmaceutical composition of claim 36 , wherein the RXR modulator is an RXR agonist.
38 . The pharmaceutical composition of claim 37 , wherein the RXR modulator is selected from
(a) bexarotene; (b) 9-cis-retinoic acid; (c) AGN-4326; (d) LGD 1324; (e) LG 100754; (f) LY-510929; (g) LGD 1268; (h) LG 100264; and (i) MX-6054.
39 . The pharmaceutical composition of claim 37 , wherein the RXR modulator is selected from a compound of Formula (VI),
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
n and m are independently 0 or 1;
R 1 and R 2 are 1) independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, hydroxyl, acyl, amino, mono-substituted amino, di-substituted amino, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide or haloalkoxy; or 2) R 1 and R 2 together with the aromatic ring bonded thereto form a cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
R 3 and R 4 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, heteroaryl, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
A is —CR 6 R7— wherein R 6 and R 7 are independently or together hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, haloalkoxy; or R 6 and R 7 together form a cycloalkyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
Ar is Formula VII, VIII, IX or X:
wherein R 8 , R 9 and R 10 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylamide, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
R 5 is hydrogen, halogen, hydroxy, alkyl or substituted alkyl;
represents a bond present or absent; and
W, X, Y and Z are independently or together —C(O)—, —C(S)—, —S—, —O—, or —NH— residues.
40 . The pharmaceutical composition of claim 36 , 37 , 38 , or 39 , wherein the glucose reabsorption inhibitor is an SGLT inhibitor.
41 . The pharmaceutical composition of claim 40 , wherein the glucose reabsorption inhibitor is an SGLT1 inhibitor.
42 . The pharmaceutical composition of claim 40 , wherein the glucose reabsorption inhibitor is an SGLT2 inhibitor.
43 . The pharmaceutical composition of claim 40 , wherein the glucose reabsorption inhibitor is selected from a dihydrochalcone, a propiophenone, and a derivative thereof.
44 . The pharmaceutical composition of claim 43 , wherein the glucose reabsorption inhibitor is a compound of Formula (V)
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
Ar is aryl or heteroaryl;
OX is an optionally protected hydroxy group;
Y is hydrogen or alkyl; and
Z is glucopyranosyl wherein one or more hydroxy groups thereof may optionally be substituted with one or more groups selected from α-D-glucopyranosyl, alkanoyl, alkoxycarbonyl, and substituted alkyl.
45 . The pharmaceutical composition of claim 44 , wherein the glucose reabsorption inhibitor is a compound of Formula (I)
wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a β-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected.
46 . The pharmaceutical composition of claim 45 , wherein the glucose reabsorption inhibitor is T-1095 or T-1095A, optionally having one or more hydroxyl or diol protecting groups, or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.
47 . A process for formulating a pharmaceutical composition, comprising formulating together a glucose reabsorption inhibitor, an RXR modulator, and a pharmaceutically acceptable carrier.
48 . The process of claim 47 , wherein the RXR modulator is an RXR agonist.
49 . The process of claim 47 , wherein the RXR modulator is selected from
(a) bexarotene; (b) 9-cis-retinoic acid; (c) AGN-4326; (d) LGD 1324; (e) LG 100754; (f) LY-510929; (g) LGD 1268; (h) LG 100264; and (i) MX-6054.
50 . The process of claim 47 , wherein the RXR modulator is a compound of Formula (VI),
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
n and m are independently 0 or 1;
R 1 and R 2 are 1) independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, hydroxyl, acyl, amino, mono-substituted amino, di-substituted amino, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide or haloalkoxy; or 2) R 1 and R 2 together with the aromatic ring bonded thereto form a cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
R 3 and R 4 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, heteroaryl, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
A is —CR 6 R 7 — wherein R 6 and R 7 are independently or together hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, haloalkoxy; or R 6 and R 7 together form a cycloalkyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
Ar is Formula VII, VIII, IX or X:
wherein R 8 , R 9 and R 10 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylamide, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
R 5 is hydrogen, halogen, hydroxy, alkyl or substituted alkyl;
represents a bond present or absent; and
W, X, Y and Z are independently or together —C(O)—, —C(S)—, —S—, —O—, or —NH— residues.
51 . The process of claims 47 , 48 , 49 , or 50 , wherein the glucose reabsorption inhibitor is an SGLT inhibitor.
52 . The process of claim 51 , wherein the glucose reabsorption inhibitor is an SGLT1 inhibitor.
53 . The process of claim 51 , wherein the glucose reabsorption inhibitor is an SGLT2 inhibitor.
54 . The process of claim 51 , wherein the glucose reabsorption inhibitor is selected from a dihydrochalcone, a propiophenone, and a derivative thereof.
55 . The process of claim 54 , wherein the glucose reabsorption inhibitor is a compound of Formula (V)
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
Ar is aryl or heteroaryl;
OX is an optionally protected hydroxy group;
Y is hydrogen or alkyl; and
Z is glucopyranosyl wherein one or more hydroxy groups thereof may optionally be substituted with one or more groups selected from α-D-glucopyranosyl, alkanoyl, alkoxycarbonyl, and substituted alkyl.
56 . The process of claim 55 , wherein the glucose reabsorption inhibitor is a compound of Formula (I)
wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a β-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected.
57 . The process of claim 56 , wherein the glucose reabsorption inhibitor is T-1095 or T-1095A, optionally having one or more hydroxyl or diol protecting groups, or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.
58 . A process for making a pharmaceutical composition comprising mixing one or more glucose reabsorption inhibitors in combination with an RXR modulator for the preparation of a medicament for treating a condition selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
59 . The process of claim 58 , wherein the RXR modulator is an RXR agonist.
60 . The process of claim 58 , wherein the RXR modulator is selected from
(a) bexarotene; (b) 9-cis-retinoic acid; (c) AGN-4326; (d) LGD 1324; (e) LG 100754; (f) LY-510929; (g) LGD 1268; (h) LG 100264; and (i) MX-6054.
61 . The process of claim 58 , wherein the RXR modulator is a compound of Formula (VI),
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
n and m are independently 0 or 1; R 1 and R 2 are 1) independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, hydroxyl, acyl, amino, mono-substituted amino, di-substituted amino, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide or haloalkoxy; or 2) R 1 and R 2 together with the aromatic ring bonded thereto form a cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
R 3 and R 4 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, heteroaryl, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
A is —CR 6 R 7 — wherein R 6 and R 7 are independently or together hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, haloalkoxy; or R 6 and R 7 together form a cycloalkyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
Ar is Formula VII, VIII, IX or X:
wherein R 8 , R 9 and R 10 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylamide, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
R 5 is hydrogen, halogen, hydroxy, alkyl or substituted alkyl;
represents a bond present or absent; and
W, X, Y and Z are independently or together —C(O)—, —C(S)—, —S—, —O—, or —NH— residues.
62 . The process of claims 58 , 59 , 60 , or 61 , wherein the glucose reabsorption inhibitor is an SGLT inhibitor.
63 . The process of claim 62 , wherein the glucose reabsorption inhibitor is an SGLT1 inhibitor.
64 . The process of claim 62 , wherein the glucose reabsorption inhibitor is an SGLT2 inhibitor.
65 . The process of claim 62 , wherein the glucose reabsorption inhibitor is selected from a dihydrochalcone, a propiophenone, and a derivative thereof.
66 . The process of claim 65 , wherein the glucose reabsorption inhibitor is a compound of Formula (V)
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
Ar is aryl or heteroaryl;
OX is an optionally protected hydroxy group;
Y is hydrogen or alkyl; and
Z is glucopyranosyl wherein one or more hydroxy groups thereof may optionally be substituted with one or more groups selected from α-D-glucopyranosyl, alkanoyl, alkoxycarbonyl, and substituted alkyl.
67 . The process of claim 66 , wherein the glucose reabsorption inhibitor is a compound of Formula (I)
wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a β-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected.
68 . The process of claim 67 , wherein the glucose reabsorption inhibitor is T-1095 or T-1095A, optionally having one or more hydroxyl or diol protecting groups, or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.
69 . A method for inhibiting the progression of a prediabetic condition in a subject to a diabetic condition, comprising
(a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to said subject a jointly effective amount of an RXR modulator, said co-administration being in any order and the combined jointly effective amounts providing the desired inhibiting effect.
70 . The method of claim 69 wherein said condition is IGT or IFG.
71 . The method of claim 69 wherein said inhibiting of the progression of a prediabetic condition is prevention of the progression of the prediabetic condition to a diabetic condition.
72 . The method of claim 71 wherein the RXR modulator is an RXR agonist.
73 . The method of claim 71 wherein the RXR modulator is selected from
(a) bexarotene;
(b) 9-cis-retinoic acid;
(c) AGN-4326;
(d) LGD 1324;
(e) LG 100754;
(f) LY-510929;
(g) LGD 1268;
(h) LG 100264; and
(i) MX-6054.
74 . The method of claim 71 wherein the RXR modulator is a compound of Formula (VI),
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
n and m are independently 0 or 1;
R 1 and R 2 are 1) independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, hydroxyl, acyl, amino, mono-substituted amino, di-substituted amino, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide or haloalkoxy; or 2) R 1 and R 2 together with the aromatic ring bonded thereto form a cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
R 3 and R 4 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, heteroaryl, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
A is —CR 6 R 7 — wherein R 6 and R 7 are independently or together hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, haloalkoxy; or R 6 and R 7 together form a cycloalkyl residue that may optionally comprise 1 or 2 heteroatoms selected from O, S, NH or N-alkyl;
Ar is Formula VII, VIII, IX or X:
wherein R 8 , R 9 and R 10 are independently or together hydrogen, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, cyano, nitro, hydroxyl, acyloxy, amino, mono-substituted amino, di-substituted amino, alkylamide, alkylsulfonamide, arylsulfonamide, alkylurea, arylurea, alkylcarbamate, arylcarbamate, alkoxy, substituted alkoxy, haloalkoxy, thioalkyl, thiohaloalkoxy; carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide;
R 5 is hydrogen, halogen, hydroxy, alkyl or substituted alkyl;
represents a bond present or absent; and
W, X, Y and Z are independently or together —C(O)—, —C(S)—, —S—, —O—, or —NH— residues.
75 . The method of claims 69 , 70 , 71 , 72 , 73 , or 74 , wherein the glucose reabsorption inhibitor is an SGLT inhibitor.
76 . The method of claim 75 wherein the glucose reabsorption inhibitor is selected from a dihydrochalcone, a propiophenone, and a derivative thereof.
77 . The method of claim 76 , wherein the glucose reabsorption inhibitor is a compound of Formula (V)
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
Ar is aryl or heteroaryl;
OX is an optionally protected hydroxy group;
Y is hydrogen or alkyl; and
Z is glucopyranosyl wherein one or more hydroxy groups thereof may optionally be substituted with one or more groups selected from α-D-glucopyranosyl, alkanoyl, alkoxycarbonyl, and substituted alkyl.
78 . The method of claim 77 , wherein the glucose reabsorption inhibitor is a compound of Formula (I)
wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a β-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected.
79 . The method of claim 78 , wherein the glucose reabsorption inhibitor is T-1095 or T-1095A, optionally having one or more hydroxyl or diol protecting groups, or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2003195235A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.